Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

This study is ongoing, but not recruiting participants.

Sponsored by:	Unidad de Investigacion Clinica en Medicina S.C.
Information provided by:	Unidad de Investigacion Clinica en Medicina S.C.
ClinicalTrials.gov Identifier:	NCT00551408

Purpose

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Condition
Pulmonary Idiopathic Arterial Hypertension

MedlinePlus related topics: High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.

Further study details as provided by Unidad de Investigacion Clinica en Medicina S.C.:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

whole blood.

Estimated Enrollment:	25
Study Start Date:	August 2007
Estimated Study Completion Date:	February 2008

Groups/Cohorts
A
B

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients with IPAH between 18 and 70 years of age of either gender were invited to participate in the study

Criteria

Inclusion Criteria:

Patients were included in the study if they were in The WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization. The ability to walk >50 m during a standardized 6-min walk test.

Exclusion Criteria:

Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, major bleeding requiring blood transfusion,renal dysfunction, and evidence for malignant diseases were excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00551408

Locations

Mexico, Nuevo Leon
Unidad de Investigacion Clinica en Medicina SC.
Monterrey, Nuevo Leon, Mexico, 64020

Sponsors and Collaborators

Unidad de Investigacion Clinica en Medicina S.C.

Investigators

Principal Investigator:

Carlos J Sanchez Diaz, MD.

Unidad de Investigacion Clinica en Medicina SC.

More Information

Study ID Numbers:	UDICEM07-012, 07-012
Study First Received:	October 29, 2007
Last Updated:	October 30, 2007
ClinicalTrials.gov Identifier:	NCT00551408
Health Authority:	Mexico: Ethics Committee; Mexico: Federal Commission for Sanitary Risks Protection

Study placed in the following topic categories:

Vascular Diseases
Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009